Retina

PPV has been a major advancement in the treatment of retinal diseases, however, little is known about its effect on oxygen metabolism in retinal vessels. In this article, Dr Sin reveals the results of his pilot study examining the effect of PPV on the oxygen saturations in retinal vessels.

During the advent of surgical approaches for retinal detachment repair, one of the most challenging cases a retinal surgeon may come across was a giant retinal tear. This article summarizes the history of GRT management and discusses current trends in surgical management.

In this article, Mr Dogramaci highlights a recent study in which he and his colleagues examined the characteristics of RRD and the relationship these characteristics have on visual outcome.

Professor Stef?nsson reveals the results of a comparative study demonstrating that observation of metabolic processes is possible enabling insight into the pathophysiology of disease.

The Transparency Commission of the French National Health Authority has issued a positive opinion for the reimbursement and hospital listing of Iluvien.

Oraya Therapeutics has announced that Oraya Therapy Stereotactic Radiotherapy for the treatment of wet AMD is now available at Optegra Manchester Eye Hospital.

Jetrea, developed by ThromboGenics, offers ?major added value? for the treatment of vitreomacula traction and macular hole, claims the German Institute for Quality and Efficiency in Health Care (IQWiG).

A combination of ketorolac eyedrops 0.45% and intravitreal ranibizumab reduces central macular thickness (CMT) in choroidal neovascularisation (CNV), reveals a recent paper.

Ozurdex, a dexamethasone implant, combined with bevacizumab successfully treats central retinal vein occlusion (CRVO), claims a recent paper.

Macula displacement is common after rhematogenous retinal detachment (RRD) repair and is heterogenous in nature, reveals a recent study.

Anti-VEGFs could be used for visual and anatomic improvements in eyes marked with submacula haemorrhage secondary to neovascular AMD, claims a study in the American Journal of Ophthalmology.

Ranibizumab has passed the one-year safety profile for neovascular age-related macular degeneration (NV-AMD), claims a recent paper.

Novartis will be the first company to offer licensed therapy ranibizumab to treat myopic choroidal neovascularisation (CNV).

The Alpha IMS, a wireless subretinal implant device, has received the CE Mark.

A paper in Retina has announced the identification of the morphologic characteristics of early onset large colloid drusen (LCD) using SD-OCT.

Examining the safety, feasability and efficacy of a fentanyl-based protocol for neonates

Non-contact ultra-widefield proves useful

Presumed Air by Vitrectomy Embolisation (PAVE) could be a fatal syndrome, states a paper in the British Journal of Ophthalmology.

What to investigate: aqueous, vitreous or both?

The incidence of retinal haemorrhages in abusive head trauma in paediatric patients for known perpetrators, regardless of a confession, is similar, reveals a paper.

Aflibercept 2.0 mg may be beneficial for cases of exudative AMD unsuccessfully treated with ranibizumab or bevacizumab, according to a recent retrospective review.

Wavelet augmented ultrasound effectively detects differences in choroidal microarchitecture in eyes with wet and dry AMD, according to a recent paper.

A new implant that allows patients suffering from advanced age-related macular degeneration (AMD) to improve their general vision and regain independence is now being implanted in the UK.

Repeated pars plana vitrectomy, with internal limiting membrane peeling and gas tamponade, is a safe and effective treatment technique for persistent macular holes, states an investigation in the Journal of Retinal and Vitreous Diseases.

Long-term positive outcomes of a minimally invasive retrobulbar episcleral brachytherapy device (SalutarisMD, Salutaris Medical Devices, London, UK) show promise for treating wet age-related macular degeneration (wAMD), according to data presented at the RCO congress.

JETREA (ThromboGenics, Leuven, Belgium) has launched in Denmark and Sweden with roll out of the drug to follow shortly in Finland and Norway. These launches will be performed by ThromboGenics partner, Alcon.

Primary endpoint results, demonstrating the non-inferiority of the BIOTRONIK Orsiro hybrid drug-eluting stent compared to Abbott?s XIENCE PRIME, from the BIOFLOW-II clinical study have been revealed at the EuroPCR congress in Paris.

The National Institute for Health and Care Excellence (NICE) has announced that Eylea (aflibercept, Bayer HealthCare, Leverkusen, Germany) should be recommended for the treatment of patients with wet age related macular degeneration (wAMD).

The variable duty cycle (DC) control on dual pneumatic ultra high-speed 23G cutters has an important effect on the vitreous flow but this is reduced at high cut rates as a result of convergence, reveals a paper in Retina.

Digital devices may be used as a visual rehabilitation technique for low-vision AMD patients, according to a paper featured in the journal Eye.